宁波艾科索医药科技

宁波艾科索医药科技 (Ningbo Aikesuo Pharmaceutical Technology) is an emerging Chinese biotechnology company focused on developing innovative small molecule therapeutics for gynecological and ophthalmic diseases. Founded in April 2024 and headquartered in Ningbo, China, the company has rapidly advanced its lead candidate, EGFNASA, into clinical development. EGFNASA is being developed as an oral capsule for the treatment of endometriosis and as a topical ointment for dry eye syndrome. In late 2025, the China National Medical Products Administration (NMPA) approved the IND application for EGFNASA capsule, and a Phase 1 clinical trial evaluating its safety, tolerability, and pharmacokinetics in healthy volunteers was initiated in December 2025. The company collaborates with leading domestic contract research organizations to accelerate its preclinical and clinical pipeline.